Abstract: The present invention relates to a humanized anti-CD20 antibody that comprises an antigen binding site containing heavy and light chain of obinutuzumab (GAZYVA®), and N-linked oligosaccharides that are attached to the Fc region of the antibody, wherein the N-linked oligosaccharides are not bisected by N-acetylglucosamine. The antibody of the present invention comprises fucose glycotype in an amount of no more than 10% of the total N-glycans that are attached to the Fc region of the antibody. The anti-CD20 of the present invention has antibody dependent cell-mediated cytotoxicity (ADCC) about 2 times stronger than that of GAZYVA® and about 50 to 100 times stronger than that of RITUXAN®. The anti-CD20 antibodies are effective for treating CD20 expressing cancer, such as non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, or follicular lymphoma.

Abstract: A plasma processing apparatus 10 includes: a first support member 81 for raising and lowering an object to be processed 200, a second support member 82 supporting a cover 70, a drive part 120 for raising and lowering the cover 70 via the second support member 82. The drive part 120, when raising the cover 70 from a lowered position to a raised position, in a first process, raises the second support member 82 without raising the first support member 81, and thus to raise the cover 70 without raising the object to be processed 200, and in a second process, raises the first and second support members 81 and 82 integrally, and thus to raise the cover 70 from the beginning of the second process, and raise the object to be processed 200 from the beginning of or after the beginning of the second process.

Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Abstract: The present disclosure provides a fixed-position defect doping method for a micro-nanostructure based on a self-alignment process, including: S1, sequentially forming a sacrificial layer and a photoresist layer on a surface of a crystal substrate; S2, performing a lithography on the photoresist layer to form a mask hole according to a micro-nano pattern; S3, performing an isotropic etching on the sacrificial layer through the mask hole, and amplifying the micro-nano pattern to the sacrificial layer; S4, performing an ion implantation doping on an exposed crystal surface below the mask hole; S5, removing the photoresist layer, and depositing a mask material; S6, removing the sacrificial layer, and transferring a micro-nano amplified pattern in the sacrificial layer to a mask material pattern; and S7, etching an exposed crystal surface, and removing the mask material on the surface and forming a specific defect by annealing.

Abstract: There is provided a display substrate, including: a base; light-emitting units on a side of the base; a flat light-shielding functional layer, including a black matrix and a first planarization layer, on a side of the light-emitting units away from the base, light outgoing openings being provided in the black matrix and being in one-to-one correspondence with the light-emitting units, and the first planarization layer at least filling the light outgoing openings; and a color filter layer, including color filter patterns in one-to-one correspondence with the light outgoing openings, on a side of the flat light-shielding functional layer away from the base, an orthographic projection of each color filter pattern on the base covering an orthographic projection of the light outgoing opening corresponding to the color filter pattern on the base. A method for manufacturing a display substrate, a display panel and a display apparatus are further provided.

Abstract: The present invention relates to a humanized anti-CD20 antibody that comprises an antigen binding site containing heavy and light chain of obinutuzumab (GAZYVA®), and N-linked oligosaccharides that are attached to the Fc region of the antibody, wherein the N-linked oligosaccharides are not bisected by N-acetylglucosamine. The antibody of the present invention comprises fucose glycotype in an amount of no more than 10% of the total N-glycans that are attached to the Fc region of the antibody. The anti-CD20 of the present invention has antibody dependent cell-mediated cytotoxicity (ADCC) about 2 times stronger than that of GAZYVA® and about 50 to 100 times stronger than that of RITUXAN®. The anti-CD20 antibodies are effective for treating CD20 expressing cancer, such as non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, or follicular lymphoma.

Abstract: The present invention relates to a humanized anti-CD20 antibody that comprises an antigen binding site containing heavy and light chain of obinutuzumab (GAZYVA®), and N-linked oligosaccharides that are attached to the Fc region of the antibody, wherein the N-linked oligosaccharides are not bisected by N-acetylglucosamine. The antibody of the present invention comprises fucose glycotype in an amount of no more than 10% of the total N-glycans that are attached to the Fc region of the antibody. The anti-CD20 of the present invention has antibody dependent cell-mediated cytotoxicity (ADCC) about 2 times stronger than that of GAZYVA® and about 50 to 100 times stronger than that of RITUXAN®. The anti-CD20 antibodies are effective for treating CD20 expressing cancer, such as non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, or follicular lymphoma.

Abstract: The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies. The present invention also relates to Chinese Hamster ovary (CHO) mutant cell line that has a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation.

Abstract: The present invention relates to a humanized anti-CD20 antibody that comprises an antigen binding site containing heavy and light chain of obinutuzumab (GAZYVA®), and N-linked oligosaccharides that are attached to the Fc region of the antibody, wherein the N-linked oligosaccharides are not bisected by N-acetylglucosamine. The antibody of the present invention comprises fucose glycotype in an amount of no more than 10% of the total N-glycans that are attached to the Fc region of the antibody. The anti-CD20 of the present invention has antibody dependent cell-mediated cytotoxicity (ADCC) about 2 times stronger than that of GAZYVA® and about 50 to 100 times stronger than that of RITUXAN®. The anti-CD20 antibodies are effective for treating CD20 expressing cancer, such as non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, or follicular lymphoma.

Abstract: The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies. The present invention also relates to Chinese Hamster ovary (CHO) mutant cell line that has a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation.

Abstract: The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies.

Abstract: An operational amplifier circuit including a main circuit, a compensation capacitor, a power circuit, and a set of switches is disclosed. The main circuit has an output terminal. The compensation capacitor has a first end connected to an internal node of the main circuit and a second end connected to the output terminal of the main circuit. The power circuit provides a current or a voltage as predetermined. The set of switches connects the power circuit to the compensation capacitor. When the main circuit is not in an output state, the set of switches is switched to allow the power circuit to provide the current or voltage to the compensation capacitor. When the main circuit is in the output state, the set of switches is switched to disconnect the power circuit from the compensation capacitor and allow the main circuit to return to an output circuit state and operate normally.

Abstract: A source driver and an operation method thereof are provided. The operation method includes following steps. A data signal is provided to the source driver. The operating current of the source driver is reduced to an abnormal operating level in period from the source driver is reset to before a pixel data of the source driver is appeared in the data signal. The operation current of the source driver is restored to a normal operating level when the pixel data of the source driver is appeared in the data signal.

Abstract: An operational amplifier circuit including a main circuit, a compensation capacitor, a power circuit, and a set of switches is disclosed. The main circuit has an output terminal. The compensation capacitor has a first end connected to an internal node of the main circuit and a second end connected to the output terminal of the main circuit. The power circuit provides a current or a voltage as predetermined. The set of switches connects the power circuit to the compensation capacitor. When the main circuit is not in an output state, the set of switches is switched to allow the power circuit to provide the current or voltage to the compensation capacitor. When the main circuit is in the output state, the set of switches is switched to disconnect the power circuit from the compensation capacitor and allow the main circuit to return to an output circuit state and operate normally.

Abstract: A method is provided for expressing recombinant proteins and polypeptides such as human serum albumin (HSA), human growth hormone (HGH), or insulin-like growth factor-I (IGF-1) in large quantities using a methylotropic or ethylotropic microorganism such as a yeast, bacteria or fungi using a dilute methanol or ethanol feeding strategy which provides for a lower flash point and can minimize the likelihood of dangerous explosion. The present invention is thus advantageous because it allows recombinant proteins to be produced on a large scale in non-explosion proof plants without the hazards associated with the use of 100% methanol which generally Ces not meet OSHA requirements, and can thus allow the safe and efficient production of large quantities of recombinant proteins and other biomaterials at a far reduced cost.